TY - JOUR
T1 - Reduced expression of p33(ING1) and the relationship with p53 expression in human gastric cancer
AU - Oki, Eiji
AU - Maehara, Yoshihiko
AU - Tokunaga, Eriko
AU - Kakeji, Yoshihiro
AU - Sugimachi, Keizo
N1 - Funding Information:
We thank M. Ohara for comments on the manuscript. This study was supported by grants from the Ministry of Education, Science, Sports and Culture of Japan.
PY - 1999/12/1
Y1 - 1999/12/1
N2 - p33(ING1) is a novel growth inhibitor candidate for a tumor suppressor gene. p33(ING1) cooperates with p53 and negatively regulates cell growth by activating transcription from the p21/WAF1 promoter even though it has no significant sequence similarity to p53. We first compared p33(ING1) expression in human gastric cancers and matched normal tissues using quantitative RT-PCR and real time 'Taqman TM' technology. A significant decrease in p33(ING1) expression was evident in 15 of 20 gastric cancers. In immunohistochemical analysis, p53 protein expression was detected in 4 of 20 (20%) tumors, and 12 of 15 (80%) tumors with decreasing p33(ING1) expression in RT-PCR had the wild type p53. When we examined the sequence of p33(ING1) in 12 gastrointestinal carcinoma cell lines, we found mutation in only one cell line, HCT116. Our findings are interpreted to mean that p33(ING1) may function as a tumor suppressor in gastric carcinogenesis, even though the gene is preserved in the majority of gastrointestinal carcinomas. It should be noted that expression of p33 decreased in many cancer patients, and the biological effects of p33(ING1) and p53 are interrelated and require the activity of both genes. Copyright (C) 1999 Elsevier Science Ireland Ltd.
AB - p33(ING1) is a novel growth inhibitor candidate for a tumor suppressor gene. p33(ING1) cooperates with p53 and negatively regulates cell growth by activating transcription from the p21/WAF1 promoter even though it has no significant sequence similarity to p53. We first compared p33(ING1) expression in human gastric cancers and matched normal tissues using quantitative RT-PCR and real time 'Taqman TM' technology. A significant decrease in p33(ING1) expression was evident in 15 of 20 gastric cancers. In immunohistochemical analysis, p53 protein expression was detected in 4 of 20 (20%) tumors, and 12 of 15 (80%) tumors with decreasing p33(ING1) expression in RT-PCR had the wild type p53. When we examined the sequence of p33(ING1) in 12 gastrointestinal carcinoma cell lines, we found mutation in only one cell line, HCT116. Our findings are interpreted to mean that p33(ING1) may function as a tumor suppressor in gastric carcinogenesis, even though the gene is preserved in the majority of gastrointestinal carcinomas. It should be noted that expression of p33 decreased in many cancer patients, and the biological effects of p33(ING1) and p53 are interrelated and require the activity of both genes. Copyright (C) 1999 Elsevier Science Ireland Ltd.
UR - http://www.scopus.com/inward/record.url?scp=0032758543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032758543&partnerID=8YFLogxK
U2 - 10.1016/S0304-3835(99)00288-8
DO - 10.1016/S0304-3835(99)00288-8
M3 - Article
C2 - 10660101
AN - SCOPUS:0032758543
SN - 0304-3835
VL - 147
SP - 157
EP - 162
JO - Cancer Letters
JF - Cancer Letters
IS - 1-2
ER -
